Skip to main content
Top
Published in: Inflammation 4/2019

01-08-2019 | Hepatitis C | ORIGINAL ARTICLE

TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response

Authors: Feng Zheng, Nannan Xu, Yajun Zhang

Published in: Inflammation | Issue 4/2019

Login to get access

Abstract

Type I interferon (IFN) response is central for host defense against viral infection. Tripartite motif 27 (TRIM27) is implicated in antiviral innate immune response; however, whether it affects the replication of hepatitis C virus (HCV) and the underlying mechanisms remain uncharacterized. Here, we show that TRIM27 expression is induced in Huh7.5 human hepatoma cells infected with HCV or stimulated with type I IFNs in vitro. In addition, TRIM27 overexpression increases and its knockdown decreases viral RNA and protein levels, suggesting that TRIM27 positively regulates HCV replication. Mechanistically, TRIM27 inhibits type I IFN response against HCV infection through inhibiting IRF3 and NF-κB pathways, since TRIM27 mutant unable to inhibit these two inflammatory pathways fails to promote HCV replication. Taken together, this study identifies TRIM27 as a novel positive regulator of HCV replication, and also implicates that targeting TRIM27 may serve as a therapeutic strategy for controlling HCV replication.
Literature
11.
go back to reference Saadoun, D., M. Resche Rigon, V. Thibault, M. Longuet, S. Pol, F. Blanc, G. Pialoux, A. Karras, D. Bazin-Karra, C. Cazorla, D. Vittecoq, L. Musset, O. Decaux, J.M. Ziza, O. Lambotte, and P. Cacoub. 2014. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 73 (5): 831–837. https://doi.org/10.1136/annrheumdis-2012-202770.CrossRefPubMed Saadoun, D., M. Resche Rigon, V. Thibault, M. Longuet, S. Pol, F. Blanc, G. Pialoux, A. Karras, D. Bazin-Karra, C. Cazorla, D. Vittecoq, L. Musset, O. Decaux, J.M. Ziza, O. Lambotte, and P. Cacoub. 2014. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 73 (5): 831–837. https://​doi.​org/​10.​1136/​annrheumdis-2012-202770.CrossRefPubMed
16.
19.
go back to reference Zhou, Z., X. Jia, Q. Xue, Z. Dou, Y. Ma, Z. Zhao, Z. Jiang, B. He, Q. Jin, and J. Wang. 2014. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proceedings of the National Academy of Sciences of the United States of America 111 (2): E245–E254. https://doi.org/10.1073/pnas.1316941111.CrossRefPubMed Zhou, Z., X. Jia, Q. Xue, Z. Dou, Y. Ma, Z. Zhao, Z. Jiang, B. He, Q. Jin, and J. Wang. 2014. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proceedings of the National Academy of Sciences of the United States of America 111 (2): E245–E254. https://​doi.​org/​10.​1073/​pnas.​1316941111.CrossRefPubMed
31.
Metadata
Title
TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response
Authors
Feng Zheng
Nannan Xu
Yajun Zhang
Publication date
01-08-2019
Publisher
Springer US
Published in
Inflammation / Issue 4/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-019-00992-5

Other articles of this Issue 4/2019

Inflammation 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.